- Degradable Starch Microspheres Transarterial Chemoembolization with or without Lipiodol for Liver Metastases from Pancreatic Cancer: A Prospective Randomized Trial
New study from Frankfurt University Hospital, Prof. Vogl has been published “Degradable Starch Microspheres Transarterial Chemoembolization with or without Lipiodol for Liver Metastases from Pancreatic Cancer: A Prospective Randomized Trial”. Check out the link below for the full article. Read More
- Magle Group enters collaboration with Sirtex Medical to support the international commercialization of EmboCept® S DSM 50 µm
Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today 2023-09-08 16:05, announces the establishment of a collaboration and exclusive worldwide distribution agreement with the global medical device company Sirtex Medial pertaining to its chemoembolization product EmboCept® S DSM 50 µm. The main purpose is to accelerate internationalization, drive growth in new geographic areas, and […]
- Magle Group initiates collaboration with leading German university hospital to explore synergies between EmboCept® S DSM 50 µm and immunotherapies
Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today 2023-06-28 11:05 announces that the company has established a collaboration with Charité – Universitätsmedizin Berlin to evaluate the combination of its vascular embolic agent EmboCept® S DSM 50 µm and immunotherapy. As a first step of the collaboration, the parties are planning a study to […]
- Positive results from post-market clinical follow-up of Magle Group’s innovative medical device SmartPAN® presented at scientific congress
Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today 2023-04-27 08:30 announces the presentation of data from the company’s first post-market clinical follow-up study of SmartPAN® – an innovative first-in-class medical device developed to improve the outcome of pancreatic surgery. The results were presented at the 140th German Surgery Congress, April 26-28th in Munich. […]
